Porton Pharma Makes China's Innovative Pharmaceuticals Decennial Honor Roll, Secures 'Industry-Leading CDMO' Title

The 2025 China Healthcare Decision Makers Conference (2025 CHDC) and the Ceremony for China's Innovative Drugs Decennial Achievements were held in Beijing. Concurrently, the list of "China's Innovative Drugs Decennial Honor" was announced, with Porton securing the honorary title of "Industry-Leading CDMO Company".

The "China’s Innovative Drugs Decennial Honor" List is designed to recognize enterprises, institutions, and major innovative achievements that have achieved outstanding results over the past decade. These selected entities have played a crucial role in driving the industrial upgrading of China's innovative pharmaceuticals and have set benchmarks for the industry's development in the next decade.

Specifically, the "Industry-Leading CDMO Company" award identifies and honors leading enterprises. These companies serve as role models in accelerating the market launch of China's innovative pharmaceuticals and reshaping the global competitive landscape.

With 20 years of in-depth engagement in the innovative pharmaceutical service, Porton has always taken innovation as its core driving force. From small molecule drugs to new modality drugs, and spanning from intermediates, active pharmaceutical ingredients (APIs) to finished formulations, Porton has continuously broken through business boundaries and technological bottlenecks.

As of June 2025, Porton has provided services to over 1,300 global clients and successfully delivered more than 4,600 projects across diverse categories. Meanwhile, Porton has proactively expanded its global presence, with its R&D and production facilities covering three core markets: China, the United States, and Europe. Committed to its mission, Porton delivers flexible, reliable, and cost-effective end-to-end CDMO solutions for innovative pharmaceutical clients worldwide.

Being selected into the honor list and receiving this award not only represents the high recognition of Porton's professional capabilities and trustworthy services from global partners, but also reflects Porton's long-term unremitting pursuit of exceptional quality and customer satisfaction.

Looking ahead, Porton will continue to uphold the philosophy of "Customer First, Strive for Excellence", working hand in hand with partners, and enabling the public's early access to good medicines!